Coherus Biosciences (CHRS) Gets a Hold from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Hold rating on Coherus Biosciences (CHRS – Research Report) yesterday. The company’s shares closed yesterday at $2.12.

McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inmune Bio, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -14.1% and a 31.85% success rate on recommended stocks.

Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $9.20.

Based on Coherus Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $91.52 million and a GAAP net loss of $79.65 million. In comparison, last year the company earned a revenue of $45.35 million and had a GAAP net loss of $58.87 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Coherus Biosciences (CHRS) Company Description:

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.